Consensus Aprea Therapeutics, Inc.

Stocks

APRE

US03836J2015

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-23 EDT			5-day change	1st Jan Change
0.5177 ^USD	-4.41%		-11.38%	-39.31%

10-14	Ladenburg Thalmann Initiates Aprea Therapeutics at Buy With $2 Price Target	MT
08-28	Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs	CI

Evolution of the Average Target: Aprea Therapeutics, Inc.

Evolution of the Target Price: Aprea Therapeutics, Inc.

Changes in Analyst Recommendations: Aprea Therapeutics, Inc.

ccfc93b8ef9833a9ab435a3.1mVbFAa8EGo201a-tlq4I3oFJTqqOswjcKZTFwH3dpI.kDdocVnwUi9xphTtzzHZQBNGblDOTKBGKtIXWWmSHPGgDBV-d90jPledDw~e96d389631967bd66af20d62575bab3c

Analysts' recommendations: Aprea Therapeutics, Inc.

10-14	Ladenburg Thalmann Initiates Aprea Therapeutics at Buy With $2 Price Target	MT
08-12	Wedbush Adjusts Aprea Therapeutics Price Target to $3 From $6, Maintains Outperform Rating	MT
05-14	Wedbush Adjusts Price Target on Aprea Therapeutics to $6 From $7, Maintains Outperform Rating	MT
05-07	Oppenheimer Initiates Aprea Therapeutics at Outperform With $5 Price Target	MT
02-10	Wedbush Cuts Price Target on Aprea Therapeutics to $7 From $11, Keeps Outperform Rating	MT
25-10-24	Aprea sees early activity in APR-1051 Wee1 trial	RE
24-03-27	Wedbush Raises Aprea Therapeutics' PT to $11 From $9 After Layering In Recent Financing, Maintains Outperform Rating	MT
23-04-10	Wedbush Raises Aprea Therapeutics' PT to $9 From $3, Says Keeps Outperform Rating; Continues to View Shares as 'Intriguingly Valued'	MT
23-03-10	Maxim Initiates Aprea Therapeutics at Buy Rating With $16 Price Target	MT
22-10-10	HC Wainwright Assumes Aprea Therapeutics at Buy with $3 Price Target	MT
22-07-07	Wedbush Initiates Aprea Therapeutics With Outperform Rating, $3 Price Target	MT
22-07-01	Berenberg Bank Terminates Coverage of 85 Companies in Consumer Discretionary, Healthcare, Industrial Tech, REIT, Software and IT Services Sectors	MT
22-05-25	Berenberg Bank Adjusts Aprea Therapeutics' Price Target to $1 From $4, Maintains Hold Rating	MT
22-03-16	HC Wainwright Adjusts Aprea Therapeutics' Price Target to $2 From $4, Maintains Neutral Rating	MT
22-03-16	RBC Trims Price Target on Aprea Therapeutics to $4 From $5, Maintains Sector Perform Rating, Speculative Risk Qualifier	MT
21-08-20	Aprea Therapeutics : JPMorgan Downgrades Aprea Therapeutics to Underweight From Neutral	MT
21-08-16	Aprea Therapeutics : HC Wainwright Adjusts Aprea Therapeutics' Price Target to $4 from $6, Keeps Neutral Rating	MT
21-08-16	Aprea Therapeutics : Berenberg Bank Downgrades Aprea Therapeutics to Hold From Buy Following Clinical Hold on Myeloid/Lymphoid Program, Adjusts PT to $4 From $10	MT
21-08-13	Aprea Therapeutics : RBC Cuts Price Target on Aprea Therapeutics to $5 From $6 Amid FDA Hold on Lymphoid Malignancy Trial; Sector Perform-Speculative Risk Rating Kept	MT
21-08-13	Aprea Therapeutics : Morgan Stanley Lowers Aprea Therapeutics to Underweight From Equal-Weight, Price Target to $3 From $5	MT
21-08-09	Aprea Therapeutics : RBC Reduces Price Target on Aprea Therapeutics to $6 From $7, Maintains Sector Perform, Speculative Risk	MT
21-05-07	Aprea Therapeutics : RBC Cuts Price Target on Aprea Therapeutics to $7 From $8, Maintains Sector Perform, Speculative Risk	MT
21-03-17	Aprea Therapeutics : RBC Cuts Price Target on Aprea Therapeutics to $8 From $10, Maintains Sector Perform-Speculative Risk Rating	MT
20-12-29	Aprea Therapeutics : Morgan Stanley Adjusts Aprea Therapeutics' Price Target to $6 From $34, Keeps Equal-Weight Rating	MT
20-12-29	Aprea Therapeutics : HC Wainwright Adjusts Aprea Therapeutics' Price Target to $6 From $30, Maintains Neutral Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	APREA THERAPEUTICS, INC.					+537.43%
	WUXI APPTEC CO., LTD.					+32.59%
	ARGENX SE					+28.09%
	LONZA GROUP AG					+10.26%
	IQVIA HOLDINGS INC.					+8.34%
	BEONE MEDICINES AG					+15.58%
	REVOLUTION MEDICINES, INC.					+38.43%
	CELLTRION, INC.					+38.53%
	GENMAB A/S					+4.99%
	WUXI BIOLOGICS (CAYMAN) INC.					+31.23%
	Average					+74.55%
	Weighted average by Cap.					+23.36%